Allogene Therapeutics, a Phase 1 biotech developing CAR-T cell therapies, filed on Friday with the SEC to raise up to $100 million in an initial public offering.
The South San Francisco, CA-based company was founded in 2017 and plans to list on the Nasdaq under the symbol ALLO. Goldman Sachs, J.P. Morgan, Cowen and Jefferies are the joint bookrunners on the deal. No pricing terms were disclosed.
